---
title: "NK1-RA plus dexamethasone linked to higher risk of new-onset diabetes during chemotherapy"
id: "pubmed-42955428"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42955428"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42955428/"
doi: "10.1007/s00520-026-11414-2"
published_at: "2026-10-29T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# NK1-RA plus dexamethasone linked to higher risk of new-onset diabetes during chemotherapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42955428
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42955428/)
- **DOI:** [10.1007/s00520-026-11414-2](https://doi.org/10.1007%2Fs00520-026-11414-2)
- **Published At:** 2026-10-29T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- A retrospective cross-sectional analysis used the DeSC health claims database covering April 2014–March 2023 to evaluate antiemetic co-administration and metabolic risk. - The cohort included adults (≥18 years) with solid tumors who initiated parenteral anticancer agents and **dexamethasone**; patients with prior diabetes or hematologic cancers were excluded. - The primary outcome was **new-onset diabetes** within two months after the index month, identified using ICD-10 diagnosis codes or prescription records. - Of 71,539 eligible patients, 51.1% received **neurokinin-1 receptor antagonists (NK1-RA)** in addition to dexamethasone. - Multivariable logistic regression showed co-administration of **NK1-RA** and **dexamethasone** was associated with increased risk (adjusted OR 1.43; 95% CI 1.31–1.55; p < 0.001). - Sensitivity analyses using alternate evaluation periods and outcome definitions produced consistent associations, according to the authors. - The study team noted ethics approval and declared no competing interests; limitations include retrospective cross-sectional design and constraints inherent to claims data. - The source did not report specific dosing regimens, timing of dexamethasone doses, nor granular clinical laboratory data to confirm hyperglycemia beyond claims-based diagnostic or prescription indicators.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42955428/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42955428%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42955428/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42955428/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42955428/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42955428/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42955428/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42955428/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42955428%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42955428%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42955428/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42955428/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42955428/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42955428/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42955428/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42955428/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42955428/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42955428/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42955428/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42955428/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42955428/#substances) Title & authors Abstract Conflict of interest statement References MeSH terms Substances Support Care Cancer Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Support+Care+Cancer%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Support+Care+Cancer%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42955428/) . 2026 Oct 29;34(11):1166. doi: 10.1007/s00520-026-11414-2. # Association of co-administration of neurokinin-1 receptor antagonists and dexamethasone with new-onset diabetes in patients receiving chemotherapy: a retrospective cross-sectional study using health claims database in Japan [Yuki Ozawa](https://pubmed.ncbi.nlm.nih.gov/?term=Ozawa+Y&cauthor_id=42955428)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-1 "Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-2 "Department of Pharmacy, Kanagawa Prefectural Keiyukai, Keiyu Hospital, Kanagawa, Japan."), [Shinya Suzuki](https://pubmed.ncbi.nlm.nih.gov/?term=Suzuki+S&cauthor_id=42955428)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-3 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan. ssuzuki@toyaku.ac.jp."), [Takuma Koinuma](https://pubmed.ncbi.nlm.nih.gov/?term=Koinuma+T&cauthor_id=42955428)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-4 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan."), [Takashi Yokokawa](https://pubmed.ncbi.nlm.nih.gov/?term=Yokokawa+T&cauthor_id=42955428)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-1 "Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."), [Takenori Ichimura](https://pubmed.ncbi.nlm.nih.gov/?term=Ichimura+T&cauthor_id=42955428)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-4 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan."), [Kenichi Suzuki](https://pubmed.ncbi.nlm.nih.gov/?term=Suzuki+K&cauthor_id=42955428)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-1 "Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."), [Yusuke Hori](https://pubmed.ncbi.nlm.nih.gov/?term=Hori+Y&cauthor_id=42955428)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-4 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan."), [Shinobu Imai](https://pubmed.ncbi.nlm.nih.gov/?term=Imai+S&cauthor_id=42955428)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#full-view-affiliation-5 "Division of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.") Affiliations Expand ### Affiliations * 1 Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. * 2 Department of Pharmacy, Kanagawa Prefectural Keiyukai, Keiyu Hospital, Kanagawa, Japan. * 3 Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan. ssuzuki@toyaku.ac.jp. * 4 Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan. * 5 Division of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan. * PMID: **42955428** * DOI: [ 10.1007/s00520-026-11414-2 ](https://doi.org/10.1007/s00520-026-11414-2) Item in Clipboard # Association of co-administration of neurokinin-1 receptor antagonists and dexamethasone with new-onset diabetes in patients receiving chemotherapy: a retrospective cross-sectional study using health claims database in Japan Yuki Ozawa et al. Support Care Cancer. 2026. Show details Display options Display options Format Abstract PubMed PMID Support Care Cancer Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Support+Care+Cancer%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Support+Care+Cancer%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42955428/) . 2026 Oct 29;34(11):1166. doi: 10.1007/s00520-026-11414-2. ### Authors [Yuki Ozawa](https://pubmed.ncbi.nlm.nih.gov/?term=Ozawa+Y&cauthor_id=42955428)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-1 "Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-2 "Department of Pharmacy, Kanagawa Prefectural Keiyukai, Keiyu Hospital, Kanagawa, Japan."), [Shinya Suzuki](https://pubmed.ncbi.nlm.nih.gov/?term=Suzuki+S&cauthor_id=42955428)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-3 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan. ssuzuki@toyaku.ac.jp."), [Takuma Koinuma](https://pubmed.ncbi.nlm.nih.gov/?term=Koinuma+T&cauthor_id=42955428)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-4 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan."), [Takashi Yokokawa](https://pubmed.ncbi.nlm.nih.gov/?term=Yokokawa+T&cauthor_id=42955428)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-1 "Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."), [Takenori Ichimura](https://pubmed.ncbi.nlm.nih.gov/?term=Ichimura+T&cauthor_id=42955428)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-4 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan."), [Kenichi Suzuki](https://pubmed.ncbi.nlm.nih.gov/?term=Suzuki+K&cauthor_id=42955428)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-1 "Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."), [Yusuke Hori](https://pubmed.ncbi.nlm.nih.gov/?term=Hori+Y&cauthor_id=42955428)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-4 "Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan."), [Shinobu Imai](https://pubmed.ncbi.nlm.nih.gov/?term=Imai+S&cauthor_id=42955428)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42955428/#short-view-affiliation-5 "Division of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.") ### Affiliations * 1 Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. * 2 Department of Pharmacy, Kanagawa Prefectural Keiyukai, Keiyu Hospital, Kanagawa, Japan. * 3 Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan. ssuzuki@toyaku.ac.jp. * 4 Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji-City, Tokyo, 192-0392, Japan. * 5 Division of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan. * PMID: **42955428** * DOI: [ 10.1007/s00520-026-11414-2 ](https://doi.org/10.1007/s00520-026-11414-2) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Purpose:** We aimed to optimize antiemetic strategies by evaluating the association of co-administration of neurokinin-1 receptor antagonist (NK1-RA) administration and dexamethasone on new-onset diabetes in patients receiving chemotherapy. **Methods:** This retrospective cross-sectional study was conducted using the DeSC database and included patients aged ≥ 18 years with solid tumors who initiated parenteral anticancer agents and dexamethasone between April 2014 and March 2023. Patients with a history of diabetes or hematologic malignancies were excluded. The primary outcome was new-onset diabetes during the 2 months following the index month, defined by International Classification of Diseases, Tenth Revision codes or prescription data. Multivariable logistic regression assessed the association between co-administration of NK1-RA and dexamethasone and new-onset diabetes. **Results:** Among 71,539 eligible patients, 51.1% received NK1-RAs. Co-administration of NK1-RA and dexamethasone was significantly associated with an increased risk of new-onset diabetes (adjusted odds ratio: 1.43; 95% confidence interval: 1.31-1.55; p - [DOI](https://doi.org/10.1007/s00520-004-0662-x) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/15278682/) 2. 1. Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242–249. - [DOI](https://doi.org/10.1016/s1470-2045\(19\)30678-3) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/31838011/) 3. 1. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral Neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119. - [DOI](https://doi.org/10.1200/jco.2003.01.095) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/14559886/) 4. 1. Minatogawa H, Izawa N, Shimomura K et al (2024) Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer 130:224–232. - [DOI](https://doi.org/10.1038/s41416-023-02493-7) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/37973958/) 5. 1. Ito Y, Tsuda T, Minatogawa H et al (2018) Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined Neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol 36:1000–1006. - [DOI](https://doi.org/10.1200/jco.2017.74.4375) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/29443652/) Show all 33 references ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42955428/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42955428/) * Antiemetics* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antiemetics%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antiemetics) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42955428/) * Antiemetics* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22A
## Related Clinical Research

- [Advanced glycation end products drive ferroptotic injury via the miR-362-3p/SLC7A11/GPX4 axis in r](https://medichelpline.com/clinical-feed/pubmed-42767451.md) (DOI: 10.1016/j.lfs.2026.124705)
- [Size-Dependent Anti-Inflammatory Nanocarriers Reduce Body Weight and Fat Without Suppressing Food](https://medichelpline.com/clinical-feed/pubmed-42708907.md) (DOI: 10.1021/acsnano.6c00432)
- [Low‑dose estradiol to treat persistent vasomotor symptoms after oophorectomy in a transgender man](https://medichelpline.com/clinical-feed/cmaj-1-estradiol-for-persistent-vasomotor-symptoms-after-surgical-menopause-in-a.md)
- [Postoperative C-Reactive Protein Predicts Delirium Incidence and Severity in Older Surgical Patien](https://medichelpline.com/clinical-feed/medrxiv-7-the-association-of-c-reactive-protein-with-delirium-severity-an-analysis-of-a.md)
- [Surgical-name Embeddings Using Large Language Models for Confounding Adjustment in Perioperative O](https://medichelpline.com/clinical-feed/medrxiv-14-large-language-model-embeddings-of-surgical-procedural-names-for-confounding.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.